Dr. Todd Hobbs, Former North American Chief Medical Officer at Novo Nordisk, to Guide Diasome's HDV Platform Expansion

CLEVELAND, OH, UNITED STATES, October 24, 2023 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel hepatocyte cell drug targeting platform, today announced the appointment of Todd Hobbs, MD as the Company's Chief Medical Officer (CMO).

Dr. Hobbs is a seasoned medical expert whose career includes diverse clinical and medical experiences. Most notably, he made significant contributions in leadership roles at Novo Nordisk for nearly eighteen years, including serving as the Chief Medical Officer in North America for seven years. Before joining industry, Dr. Hobbs spent the earlier part of his career in clinical practice, focusing on the intensive management of diabetes patients of all ages. Additionally, his stewardship as the chairman of a large regional medical center's medicine department in Kentucky provides an invaluable perspective on the real-world clinical utility of Diasome's products.

At Diasome, Dr. Hobbs will spearhead the clinical development of the company's Hepatocyte Directed Vesicles (HDV™) platform. His immediate focus will encompass guiding Diasome's HDV™ insulin Phase 2b trial (the “OPTI-2” study) and expanding the company's efforts into Oral HDV™ GLP-1 and other innovative strategies targeting insulin resistance's root cause.

Dr. Hobbs' academic credentials include a medical degree from the University of Louisville School of Medicine, complemented by executive training from the Wharton School of Business at the University of Pennsylvania.

Robert Geho, CEO at Diasome Pharmaceuticals, remarked, "We are delighted to have Dr. Hobbs join our team. His commitment to improving the lives of people with diabetes fits perfectly with Diasome’s mindset and focus. His unique blend of clinical expertise and leadership experience will be critical to driving the expansion of our HDV platform. We're confident that under Dr. Hobbs’ stewardship, Diasome will continue to break new ground in metabolic disease treatment."

Sharing his enthusiasm, Dr. Hobbs said, "Joining Diasome is an exciting new chapter for me, and one that brings me back to the source of my passion caring for those living with diabetes. The Company's pioneering approach, especially with the HDV platform, has the potential to redefine metabolic disease treatment for countless numbers of patients. I'm eager to contribute to this transformative journey."

Commenting on Dr. Hobbs' appointment, Steven St. Peter, MD, Managing Director of the JDRF T1D Fund, stated: "Diasome is a company innovating to address unmet patient need in T1D, and the Fund is proud to work alongside the company’s management team – including Dr. Hobbs – as they advance their high impact work.”

About Diasome Pharmaceuticals, Inc.: Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasome's Hepatocyte Targeting Platform re-establishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocyte's natural regulatory functions.

For additional details about Diasome Pharmaceuticals, Inc., please visit www.diasome.com

Kent Manson
Diasome Pharmaceuticals
+1 720-891-7644
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.